Puma Biotechnology Releases Updated Corporate Presentation
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
After making $1M+ on illegal trades, former Puma Biotechnology executive gets prison term | Fierce Pharma
Puma Biotechnology Inc
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology - Crunchbase Company Profile & Funding
/https%3A%2F%2Fstatic.stocktitan.net%2Fcompany-logo%2Fpbyi-lg.png "Puma Biotechnology Inc (PBYI) Stock Price Today, News, Quotes, FAQs and Fundamentals")
Puma Biotechnology Inc (PBYI) Stock Price Today, News, Quotes, FAQs and Fundamentals
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | Evaluate
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology to Participate in Panel Discussion at Citi's Biotech Conference
Puma Biotechnology Publishes P-II Trial (TBCRC041) Results of Alisertib for Endocrine-Resistant Advanced Breast Cancer in JAMA Oncology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Biotechnology
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
